Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
The Chain: Protein Engineering Podcast

Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D

B2Upper-intermediateJune 9, 202653 min

At this year’s PEGS Boston, industry experts gathered on a panel to explore how AI and machine learning are deployed in biologics R&D today. Moderated by Peter M. Tessier, Ph.D., Albert M. Mattocks professor of pharmaceutical sciences and chemical engineering at University of Michigan, the panel consisted of Andrew Buchanan, Ph.D., head of discovery at a stealth-mode biotech company; Norbert Furtmann, Ph.D., head of biologics AI and design of large molecules research at Sanofi; Konrad S. Krawczyk, Ph.D., founder and CSO at NaturalAntibody SA; Andrew C.R. Martin, Ph.D., emeritus professor of bi...

Play episode

Opens the player: the full transcript, every word clickable, with translation and flashcards.

Try it: tap any word

Real sentences from the start of this episode. Every word is marked with its level.

Sentence 8 of 12 · 0:41

So before we get started, I just want to introduce this distinguished panel. So first, Melody

, .

And her group really is involved in helping make data and models available and usable for both wet

Tap a word to see its meaning in your language.

Do you know these words?

8 harder words from this episode. Tap one to see what it means, then mark it.

Mark a few words and we'll tell you how this episode fits your level.

Is this episode right for you?

B2

B2 · Upper-intermediate

Comfortable if you already follow TV news

A1 27%A2 35%B1 21%B2 13%C1 4%
  • 83% of the words are B1 or easier.
  • 165 words a minute: natural, fairly fast speech.
  • 223 harder words (B2 and up) in the whole episode.

Transcript

The opening of the episode. The whole transcript is in the player.

0:00

Welcome to The Chain, the podcast covering the lives, careers, research, and discoveries of protein engineers, scientists, and biotech professionals. In today's special episode, we hear a panel discussion on near-term challenges for ML and AI in biotherapeutic R&D recorded live at the PEGS Summit in May in Boston.

0:24

Peter Tessier, Albert M. Maddox Professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, moderates the conversation. Here he is, introducing the panel. So before we get started, I just want to introduce this distinguished panel. So first, Melody Schass-Savarian, who's Senior Director of Data Strategy and Digital Transformation at Eli Lilly.

0:48

And her group really is involved in helping make data and models available and usable for both wet lab and dry lab scientists across biologics discovery and optimization. Andrew Martin, who's an emeritus professor of bio informatics and computational biology at University College London. Of course, a lot of us know him for he's a co-founder of I call it abscess or abecis.

That was the opening. The rest of the episode (53 min) is in the player: every word clickable, with translation, saved words and flashcards.

Continue in the player

Automatically generated from the audio. May contain errors. Audio belongs to its publisher and is played from their feed. Rights holders can request removal — copyright & takedown policy